MARKET

CODX

CODX

Co-Diagnostics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.83
-0.03
-0.30%
After Hours: 9.61 -0.22 -2.24% 18:47 07/29 EDT
OPEN
9.97
PREV CLOSE
9.86
HIGH
10.15
LOW
9.63
VOLUME
647.56K
TURNOVER
--
52 WEEK HIGH
30.99
52 WEEK LOW
7.01
MARKET CAP
283.89M
P/E (TTM)
5.62
1D
5D
1M
3M
1Y
5Y
75 Biggest Movers From Friday
Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global Management for $9 per share in all-cash transaction.
Benzinga · 3d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/22 20:45
Why Co-Diagnostics Shares Are Skyrocketing Today
Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher by 26.3% at $10.99 Thursday afternoon. The stock spiked earlier following reports suggesting the Biden Administration will announce it is directing $1.6 billion for COVID testing in high-risk sett...
Benzinga · 07/22 18:33
Co-Diagnostics gets Republic of Korea patent for its CoPrimer technology
Co-Diagnostics ([[CODX]]) has been awarded a patent from the Republic of Korea's Intellectual Property Office for the company's CoPrimer technology.CoPrimer technology received its first patent from the United States Patent
Seekingalpha · 07/22 14:27
Co-Diagnostics Highlights New International CoPrimer Patent
Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual
Benzinga · 07/22 13:31
Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent
 /PRNewswireCo-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a p...
PR Newswire - PRF · 07/22 13:30
Co-Diagnostics Obtains South Korea Patent for CoPrimer; Shares Rise 6% Midday
MT Newswires · 07/22 13:06
Strength Seen in CoDiagnostics, Inc. (CODX): Can Its 9.7% Jump Turn into More Strength?
Zacks.com · 07/20 07:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CODX. Analyze the recent business situations of Co-Diagnostics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CODX stock price target is 23.00 with a high estimate of 30.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 9.41M
% Owned: 32.57%
Shares Outstanding: 28.88M
TypeInstitutionsShares
Increased
27
1.22M
New
21
688.22K
Decreased
30
435.81K
Sold Out
12
218.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.96%
Healthcare Equipment & Supplies
+0.72%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dwight Egan
Chief Financial Officer/Secretary
Brian Brown
General Counsel
Reed Benson
Independent Director
Eugene Durenard
Independent Director
Edward Murphy
Independent Director
James Nelson
Independent Director
Richard Serbin
No Data
  • All
  • Financials
  • Insiders
More
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Webull offers kinds of Co-Diagnostics Inc stock information, including NASDAQ:CODX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CODX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CODX stock methods without spending real money on the virtual paper trading platform.